Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M923Revenue $M74.0Net Margin (%)-200.7Z-Score-3.7
Enterprise Value $M909EPS $-2.3Operating Margin %-8.2F-Score4
P/E(ttm))0Cash Flow Per Share $-1.7Pre-tax Margin (%)-200.8Higher ROA y-yN
Price/Book10.610-y EBITDA Growth Rate %0Quick Ratio0.9Cash flow > EarningsY
Price/Sales4.85-y EBITDA Growth Rate %0Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-143.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-523.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M74.8ROI % (ttm)-72.1Gross Margin Increase y-yY

Gurus Latest Trades with HZNP

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HZNPJoel Greenblatt 2014-06-30 Buy 0.01%$12.02 - $16.32
($14.25)
$ 12.34-13%New holding, 57769 sh.57,769
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HZNP is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HZNP Joel Greenblatt 2014-06-3057,7690.080.01New Buy
Premium Most recent portfolio changes are included for Premium Members only!


HZNP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
DE VAERE ROBERT JEVP & CFO 2014-09-30Sell51,942$12.282.2view
Walbert Timothy PPresident, Chairman and CEO 2014-05-19Sell31,742$12.94-3.01view
SMITH TODD NEVP & Chief Commercial Officer 2014-05-19Sell10,159$12.94-3.01view
SHERMAN JEFFREY WEVP & Chief Medical Officer 2014-05-19Sell9,361$12.94-3.01view
DE VAERE ROBERT JEVP & CFO 2014-05-19Sell12,939$12.94-3.01view
BIRD JEFFREY WDirector 2013-12-13Buy32,075$6.593.08view
BIRD JEFFREY WDirector 2013-12-13Buy668,673$6.593.08view
Walbert Timothy PPresident, Chairman and CEO 2013-12-09Sell12,124$6.7984.83view
SMITH TODD NEVP & Chief Commercial Officer 2013-12-09Sell11,322$6.9181.62view
BIRD JEFFREY WDirector 2013-11-21Buy151,089$6.24101.12view

Press Releases about HZNP :

    Quarterly/Annual Reports about HZNP:

    News about HZNP:

    Articles On GuruFocus.com
    Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc. Oct 17 2014 
    Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of A Oct 15 2014 
    Horizon Pharma plc Reviews Future ACTIMMUNE(R) Opportunities at Analyst Day Oct 15 2014 
    Horizon Pharma plc Receives Orphan-Drug Designation for ACTIMMUNE(R) (Interferon gamma-1b) in Friedr Oct 15 2014 
    Horizon Pharma plc Announces Presentation of ACTIMMUNE(R) Phase 2 Data in Friedreich's Ataxia Oct 15 2014 

    More From Other Websites
    Horizon Pharma plc to Host Third Quarter 2014 Conference Call and Webcast on November 6, 2014 Oct 21 2014
    Horizon Pharma plc to Host Third Quarter 2014 Conference Call and Webcast on November 6, 2014 Oct 21 2014
    ZetrOZ, Inc. Announces $5 Million Venture Loan Facility from Horizon Technology Finance to Fuel... Oct 20 2014
    NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon Oct 20 2014
    HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Oct 17 2014
    Nuvo Sells Pennsaid 2% U.S. Rights for US$45M to Horizon Pharma Oct 17 2014
    Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc. Oct 17 2014
    Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc. Oct 17 2014
    HORIZON PHARMA PLC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements... Oct 14 2014
    Horizon Pharma plc Reviews Future ACTIMMUNE(R) Opportunities at Analyst Day Oct 13 2014
    Horizon Pharma plc Announces Presentation of ACTIMMUNE(R) Phase 2 Data in Friedreich's Ataxia Oct 09 2014
    Horizon Pharma's Actimmune Gets Orphan Drug Designation Oct 07 2014
    Horizon Pharma plc Receives Orphan-Drug Designation for ACTIMMUNE(R) (Interferon gamma-1b) in... Oct 03 2014
    Jazz Pharmaceuticals Uses New Cash To Buy For Growth Oct 03 2014
    The Zacks Analyst Blog Highlights: Super Micro Computer, Horizon Pharma, Phibro Animal Health,... Oct 02 2014
    Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of... Oct 01 2014
    The Bigger The Base The Higher Into Space It Goes Sep 29 2014
    HORIZON PHARMA PLC Files SEC form 8-K, Change in Directors or Principal Officers Sep 26 2014
    Horizon Pharma plc Announces Management Executive Committee and Commercial Restructuring Following... Sep 26 2014
    HORIZON PHARMA PLC Financials Sep 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK